CO5200772A1 - Mesoprogestinas (moduladores de receptores de progesterona) para el trataiento y la prevencion de transtornos ginecolo- gicos benignos hormona-dependientes - Google Patents

Mesoprogestinas (moduladores de receptores de progesterona) para el trataiento y la prevencion de transtornos ginecolo- gicos benignos hormona-dependientes

Info

Publication number
CO5200772A1
CO5200772A1 CO00065515A CO00065515A CO5200772A1 CO 5200772 A1 CO5200772 A1 CO 5200772A1 CO 00065515 A CO00065515 A CO 00065515A CO 00065515 A CO00065515 A CO 00065515A CO 5200772 A1 CO5200772 A1 CO 5200772A1
Authority
CO
Colombia
Prior art keywords
progesterone
treatment
prevention
disorders
mcphail
Prior art date
Application number
CO00065515A
Other languages
English (en)
Spanish (es)
Inventor
Walter Elger
Chwalisz Kristof
Gerd Schubert
Original Assignee
Jenapharm Gmbh And Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenapharm Gmbh And Co Kg filed Critical Jenapharm Gmbh And Co Kg
Publication of CO5200772A1 publication Critical patent/CO5200772A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32Antioestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34Gestagens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
CO00065515A 1999-08-31 2000-08-31 Mesoprogestinas (moduladores de receptores de progesterona) para el trataiento y la prevencion de transtornos ginecolo- gicos benignos hormona-dependientes CO5200772A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38614199A 1999-08-31 1999-08-31

Publications (1)

Publication Number Publication Date
CO5200772A1 true CO5200772A1 (es) 2002-09-27

Family

ID=23524338

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00065515A CO5200772A1 (es) 1999-08-31 2000-08-31 Mesoprogestinas (moduladores de receptores de progesterona) para el trataiento y la prevencion de transtornos ginecolo- gicos benignos hormona-dependientes

Country Status (34)

Country Link
EP (1) EP1229906B1 (https=)
JP (1) JP2003535029A (https=)
KR (3) KR20080066095A (https=)
AR (1) AR025457A1 (https=)
AT (1) ATE375160T1 (https=)
AU (1) AU781840B2 (https=)
BG (1) BG65817B1 (https=)
BR (1) BR0014161A (https=)
CA (1) CA2382580C (https=)
CO (1) CO5200772A1 (https=)
CZ (1) CZ2002704A3 (https=)
DE (1) DE60036723T2 (https=)
DK (1) DK1229906T3 (https=)
EA (1) EA007854B1 (https=)
EE (1) EE05172B1 (https=)
ES (1) ES2295050T3 (https=)
HR (1) HRP20020267A2 (https=)
HU (1) HUP0202429A3 (https=)
IL (1) IL148416A0 (https=)
LT (1) LT5034B (https=)
LV (1) LV12941B (https=)
ME (1) MEP13808A (https=)
MX (1) MXPA02002191A (https=)
NO (1) NO20020999L (https=)
NZ (1) NZ517471A (https=)
PE (1) PE20010578A1 (https=)
PL (1) PL198790B1 (https=)
PT (1) PT1229906E (https=)
RO (1) RO122179B1 (https=)
RS (1) RS50283B (https=)
SI (1) SI20852B (https=)
SK (1) SK287192B6 (https=)
UA (1) UA78184C2 (https=)
WO (1) WO2001015679A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003255355A1 (en) * 2002-08-02 2004-02-25 Schering Aktiengesellschaft Progesterone receptor modulators having an increased antigonadotropic activity for use in female fertility testing and hormone replacement therapy
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
US20040097591A1 (en) * 2002-11-18 2004-05-20 Kristof Chwalisz Use of selective progesterone receptor modulators for the treatment of androgen deficiency
RU2301691C1 (ru) * 2005-12-20 2007-06-27 Государственное учреждение Научный центр акушерства, гинекологии и перинатологии Российской академии медицинских наук Способ восстановительного лечения женщин репродуктивного возраста с тазовыми перитонеальными спайками с фиксированной или субфиксированной ретродевиацией матки
DE102007011105A1 (de) 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
RU2339392C1 (ru) * 2007-05-21 2008-11-27 Федеральное Государственное учреждение Научный центр акушерства, гинекологии и перинатологии Росмедтехнологий Способ остановки маточных кровотечений в пубертатном периоде
JP4709328B2 (ja) * 2009-06-17 2011-06-22 国立大学法人 熊本大学 月経困難症の予防及び/又は治療薬
US8399432B2 (en) * 2009-10-27 2013-03-19 Lipogen Ltd. Compositions and methods of treatment for alleviating premenstrual syndrome symptoms
JP2022548314A (ja) * 2019-09-23 2022-11-17 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 妊娠を遷延させるためおよび月経または妊娠の合併症の処置の方法
US12426782B2 (en) 2020-11-06 2025-09-30 The Board Of Trustees Of The Leland Stanford Junior University Systems and temporal alignment methods for evaluation of gestational age and time to delivery

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3633244A1 (de) 1986-09-26 1988-03-31 Schering Ag Antigestagene zur hemmung der uterinen prostaglandinsynthese
DE4332284C2 (de) 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5681817A (en) * 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
US5576310A (en) * 1994-09-20 1996-11-19 Jenapharm Gmbh 11-benzaldoxime-17β-methoxy-17α-methoxymethyl-estrasdiene derivatives, methods for their production and pharmaceuticals containing such compounds
US5696127A (en) * 1994-12-22 1997-12-09 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
EP1043325B1 (en) * 1994-12-22 2004-06-16 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
UA37259C2 (uk) 1995-02-02 2001-05-15 Шерінг Актієнгезеллшафт Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч
DE19604231A1 (de) * 1996-01-29 1997-07-31 Schering Ag Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen
WO1997041145A1 (en) * 1996-05-01 1997-11-06 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services 21-substituted progesterone derivatives as new antiprogestational agents
WO1998005679A2 (en) * 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19809845A1 (de) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
EP1144396A2 (en) * 1999-01-14 2001-10-17 Bayer Corporation Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
HK1043788A1 (zh) * 1999-05-04 2002-09-27 American Home Products Corporation 四環黃體酮受體調節劑化合物及方法

Also Published As

Publication number Publication date
ATE375160T1 (de) 2007-10-15
PL353930A1 (en) 2003-12-15
CA2382580C (en) 2009-05-19
PT1229906E (pt) 2008-01-18
RS50283B (sr) 2009-09-08
KR20070058023A (ko) 2007-06-07
HUP0202429A3 (en) 2004-04-28
LT5034B (lt) 2003-07-25
WO2001015679A3 (en) 2001-11-22
EE05172B1 (et) 2009-06-15
UA78184C2 (en) 2007-03-15
MEP13808A (en) 2010-06-10
JP2003535029A (ja) 2003-11-25
SI20852A (sl) 2002-10-31
DE60036723D1 (de) 2007-11-22
EE200200104A (et) 2003-04-15
AU781840B2 (en) 2005-06-16
KR20020027616A (ko) 2002-04-13
ES2295050T3 (es) 2008-04-16
KR100864547B1 (ko) 2008-10-20
NZ517471A (en) 2004-02-27
DK1229906T3 (da) 2008-02-11
EA200200282A1 (ru) 2002-10-31
WO2001015679A2 (en) 2001-03-08
CZ2002704A3 (cs) 2003-02-12
AU6946600A (en) 2001-03-26
PE20010578A1 (es) 2001-06-04
CA2382580A1 (en) 2001-03-08
NO20020999L (no) 2002-03-14
YU14002A (sh) 2006-01-16
DE60036723T2 (de) 2008-07-17
BG65817B1 (bg) 2010-01-29
SK287192B6 (sk) 2010-02-08
HUP0202429A2 (en) 2002-10-28
BR0014161A (pt) 2002-05-21
EA007854B1 (ru) 2007-02-27
KR100755109B1 (ko) 2007-09-04
EP1229906A2 (en) 2002-08-14
AR025457A1 (es) 2002-11-27
NO20020999D0 (no) 2002-02-28
BG106442A (bg) 2002-09-30
MXPA02002191A (es) 2002-09-30
EP1229906B1 (en) 2007-10-10
RO122179B1 (ro) 2009-02-27
PL198790B1 (pl) 2008-07-31
SK2992002A3 (en) 2002-07-02
LT2002031A (en) 2003-02-25
SI20852B (sl) 2009-06-30
IL148416A0 (en) 2002-09-12
HRP20020267A2 (en) 2004-04-30
LV12941B (en) 2003-06-20
KR20080066095A (ko) 2008-07-15

Similar Documents

Publication Publication Date Title
CO5200772A1 (es) Mesoprogestinas (moduladores de receptores de progesterona) para el trataiento y la prevencion de transtornos ginecolo- gicos benignos hormona-dependientes
AR011480A1 (es) ACIL-ANILIDAS SUSTITUIDAS CON RADICALES (HETERO) CICLICOS, NO ESTEROIDALES, CON ACTIVIDAD GESTÁGENA Y ANDRoGENA MIXTA.
ES2610654T3 (es) Anticuerpos neutralizantes del receptor de prolactina y su uso terapéutico
ES2218556T3 (es) Metodos de contracepcion.
MXPA05005897A (es) Derivados tetraciclicos novedosos, que contienen heteroatomos, como moduladores selectivos del receptor de estrogeno.
BR112013003668A2 (pt) associação farmacêutica para tratar e/ou prevenir mioma e/ou endometriose, uso de resveratrol e progestogênio, composição farmacêutica para tratamento e/ou prevenção de mioma e/ou endometriose
CR7611A (es) Uso de derivados de cilotiocarbamato en tratamiento de condiciones relacionadas con la hormona
CO5261567A1 (es) Uso de sulfamatos estrogenos biogenicos en una terapia de reemplazo de hormonas
CO5190694A1 (es) Mesoprogestinas (moduladores de receptores de progesterona) como componentes de anticonceptivos femeninos
Saunders Effects of sex steroids and related compounds on pregnancy and on development of the young.
CO5200773A1 (es) Mesoprogestinas (moduladores de receptores para progestero- na) como componente de composiciones utilizadas para la terapia de sustitucion hormonal (trh)
Hahn et al. The pharmacological profile of norgestimate, a new orally active progestin
WO2002056903A3 (en) Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
Murray Natural progesterone: what role in women’s health care
JP2003535029A5 (https=)
UY26665A1 (es) Estratrienos sustituidos como estrógenos selectivamente activos
ES2231356T3 (es) Uso de un antagonista del receptor de la progesterona para impedir la fertilizacion.
MX363979B (es) Forma de dosificacion de un antagonista del receptor de progesterona.
Sanz et al. A review of the ovarian synchronization programs based on the use of gonadotrophin releasing hormone and prostaglandin F2α for dairy and beef heifers.
ŁKARDA Detection of estrogenicity by bioassay on the mouse mammary gland in vivo
Garcia et al. Characteristics of ejaculated rat semen after lesion of scrotal nerves
Van der Schoot et al. Interactions between oestradiol and the progesterone antagonist RU-486 in establishing and maintaining female rats' sexual responsiveness: central versus peripheral effects
Dalterio et al. Effects of Δ9-THC and castration on behavior and plasma hormone levels in male mice
Liu et al. Effect of some oral contraceptive steroids on the development of endometrial squamous metaplasia and cysts in rats
PE20030411A1 (es) DERIVADOS 8ß-SUSTITUIDOS DE 11ß-FENIL Y 11ß-HEXIL-ESTRA-1,3,5(10)-TRIENO QUE TIENEN AFINIDAD POR RECEPTORES DE ESTROGENO

Legal Events

Date Code Title Description
FC Application refused